Open Access Articles- Top Results for Urofollitropin


Clinical data
Trade names Bravelle, Fertinex
AHFS/ Micromedex Detailed Consumer Information
  • US: X (Contraindicated)
Subcutaneous, intramuscular
146479-72-3 7pxY
PubChem CID 62819
DrugBank DB00094 7pxN
KEGG D06400 7pxY
ChEMBL CHEMBL1201520 7pxN
Chemical data
Formula C975H1513N267O304S26
22672.9 g/mol
 14pxN (what is this?)  (verify)

Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified[1] to remove various proteins and other substances. FSH is important in the development of follicles (eggs) produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility.[2] It is also used with in vitro fertilization methods. The dosage is adjusted to each individual's response.[2]

The most common side effects are abdominal or pelvic pain, bloating, as well as redness, pain or swelling at the injection site. Follitropin is possibly associated with increased risk of endometrial carcinoma. It is not for use during pregnancy, as there is evidence for birth defects under follitropin treatment.[2]


  1. ^ Van Wely, M.; Yding Andersen, C.; Bayram, N.; Van Der Veen, F. (2005). "Urofollitropin and ovulation induction". Treatments in endocrinology 4 (3): 155–165. PMID 15898821.  edit
  2. ^ a b c Urofollitropin (Intramuscular route, Subcutaneous route, Injection route)

External links

  • Bravelle, by Ferring Pharmaceuticals, Switzerland
  • Fostimon by Institut Biochemique SA, Switzerland